Compositions and methods for the treatment of skin diseases
AssigneeKrystal Biotech, Inc.
InventorsSuma Krishnan, Pooja Agarwal, Trevor Parry
Life of this patent
Estimating the term…
Abstract
Provided herein are recombinant nucleic acids comprising one or more polynucleotides encoding a laminin polypeptide and/or a filaggrin polypeptide; viruses comprising the recombinant nucleic acids; compositions and formulations comprising the recombinant nucleic acids and/or viruses; methods of their use; and articles of manufacture or kits thereof.
Claims10
A pharmaceutical composition useful for delivery of one or more polynucleotides encoding a human filaggrin polypeptide to the skin of a subject having a skin disease, the pharmaceutical composition comprising:
- a) a herpes simplex virus comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises the one or more polynucleotides encoding the human filaggrin polypeptide;
- and
- b) a pharmaceutically acceptable excipient,
- wherein the skin disease is selected from the group consisting of atopic dermatitis, ichthyosis vulgaris, and a peeling skin syndrome,
- wherein the one or more polynucleotides encoding the human filaggrin polypeptide does not comprise a ribonucleic acid (RNA), and
- wherein the recombinant herpes simplex virus genome does not comprise a polynucleotide encoding a collagen polypeptide, a fibronectin polypeptide, an elastin polypeptide, a lumican polypeptide, a vitronectin polypeptide, a vitronectin receptor polypeptide, a neuromodulator polypeptide, a fibrillin polypeptide, a laminin polypeptide, or a transglutaminase polypeptide.
A method of providing prophylactic, palliative, or therapeutic relief of one or more signs or symptoms of a skin disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising;
- a) a herpes simplex virus comprising a recombinant herpes simplex virus genome, wherein the recombinant herpes simplex virus genome comprises one or more polynucleotides encoding a human filaggrin polypeptide;
- and
- b) a pharmaceutically acceptable excipient,
- wherein the skin disease is selected from the group consisting of atopic dermatitis, ichthyosis vulgaris, and a peeling skin syndrome,
- wherein the one or more polynucleotides encoding the human filaggrin polypeptide does not comprise a ribonucleic acid (RNA), and
- wherein the recombinant herpes simplex virus genome does not comprise a polynucleotide encoding a collagen polypeptide, a fibronectin polypeptide, an elastin polypeptide, a lumican polypeptide, a vitronectin polypeptide, a vitronectin receptor polypeptide, a neuromodulator polypeptide, a fibrillin polypeptide, a laminin polypeptide, or a transglutaminase polypeptide.
Dependencies are inferred from the claim text.